期刊文献+

化学发光免疫分析法测定血浆B型钠尿肽的评价及其参考区间调查 被引量:5

Evaluation of an immunochemiluminescence assay for human plasma B-type natriuretic peptide(BNP) and the reference interval of BNP
下载PDF
导出
摘要 目的评价血浆B型钠尿肽(BNP)的化学发光免疫分析法(CLIA)以了解其检测性能,同时调查国人参考区间。方法用Biosite公司的TriageBNP试剂盒,在Beckman Coulter AccessⅡ上测定,参照EP文件,对该方法的线性、测定下限、灵敏度、精密度、抗干扰能力进行评价,观察BNP的体外稳定性;选择表观健康人共421名(男202名,女219名),按性别,以10岁为一个间隔分为6个年龄组,测定EDTA抗凝血浆中的BNP浓度,并确立各年龄和性别组的参考区间。结果CLIA法测定人血浆BNP的线性范围15-5040ng/L,测定下限9.2ng/L;灵敏度1.4ng/L;CV10%处为30ng/L;胆红素〈253μmol/L、Hb浓度〈4g/L、TG〈12.88mmol/L对BNP测定无影响。BNP在全血中室温可稳定8h,4oC可稳定24h;在血浆中室温可稳定6h,4℃可稳定8h,-70℃稳定6个月。BNP随年龄逐渐升高,女性高于男性。〈55岁者年龄差异无统计学意义(P〉0.05),但性剐差异有统计学意义(P〈0.05),男性P975为34.5ng/L,女性为57.8ng/L;〉55岁者性剐间无差异(P〉0.05),55-74岁P95 63.6ng/L,%596ng/L;I〉75岁者%99.7ng/L,%5为100.7ng/L。结论测定BNP的CLIA法线性范围宽,灵敏度高,测定下限、检测精密度以及抗干扰能力均能满足临床要求;BNP在常规条件下保存时稳定性良好。建议采用单侧P97.5作为参考区间,〈55岁男性为〈34.5ng/L,女性为〈57.8ng/L;55岁以上不分性别均为〈100.4ng/L。 Objective To evaluate an immunochemilumineseence assay for human plasma B-type natriuretic peptide (BNP), and to investigate the reference interval of BNP in healthy Chinese. Methods EDTA anti-coagulant plasmas from 421 healthy volunteers (202 men and 219 women) were included. BNP was measured with Triage BNP kit developed by Biosite on the Beckman Coulter Access II. Referring to the EP documents, a series of tests were designed to investigate the assay's linearity, detection limit, sensitivity, precision,interference factors,and BNP's stability under different storage conditions. Results The assay had a linearity of 15 -5 040 ng/L,and the detection limit was 9.2 ng/L. The concentration at 10% of CV was 30 ng/L. There was no obvious interference in the assay when bilirubin was 〈 253 μmol/L, hemoglobin was 〈 4 g/L, or triglyceride was 〈 12.88 mmol/L. In whole blood, BNP could be stable for 8h at room temperature and for 24 h at 4℃;in plasma, it could be stable for 6h at room temperature, 8h at 4℃, and at least for 6 months at -70℃. BNP was higher in female than in male (P 〈0.05) ;the 97.5% percentile was 34.5 ng/L for male and 57.8 ng/L for female. The 97.5% percentile for 55 -74 years old persons was 96 ng/L, and that for 〉75 years old persons was 100.7 ng/L. Conclu, sion The immunochemiluminescence assay for human BNP is highly sensitive. The characteristic of its wide detection linearity, precision,and anti-interference ability meets the clinical requirement. We recommend that the 97.5% percentile be a reference interval; when the age is 〈 55 years old, the value is 〈 34.5 ng/L for male and 〈 57.8 ng/L for female ; when the age is 〉 55 years old, the value is 〈 100.4 ng/L for both genders.
出处 《临床检验杂志》 CAS CSCD 北大核心 2009年第4期283-285,共3页 Chinese Journal of Clinical Laboratory Science
关键词 B型钠尿肽 免疫化学发光 方法学评价 稳定性 参考区间 B-type natriuretic peptide methodology evaluation stability reference interval
  • 相关文献

参考文献9

  • 1Jourdain P, Joudeau G, Funk F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARSBNP Muhicenter Study[J]. J Am Coll Cardiol, 2007,49 (16) : 1733 -1739.
  • 2史晓敏,徐国宾,夏铁安.B型尿钠肽的生物学特性及其测定的临床应用[J].临床检验杂志,2005,23(1):67-70. 被引量:46
  • 3Mair J, Gerda F, Renate H, et al. Head-to-head comparison of B- type natriuretic peptide(BNP) and NT-proBNP in daily clinical practice[J]. Int J Cardiol,2008,124(2) :244-246.
  • 4Richard M, Nicholls MG, Espiner EA, et al. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease [ J ]. J Am Coll Cardiol, 2006,47 (1):52-60.
  • 5Steq P G, Joubin L, McCord J, et al. B-type natriuretic peptide and echocardiographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea[J]. Chest, 2005,128( 1 ) :21-29.
  • 6Azzazy H M, Christenson R H, Duh S H. Stability of B-type natriuretic peptide (BNP) in whole blood and plasma stored under different conditions when measured with the Biosite Triage or Beckman-Coulter Access systems[ J]. Clin Chim Acta,2007,384 (1-2) : 176-178.
  • 7Chien T I, Chen H H, Kao J T. Comparison of Abbott AxSYM and Roche Elecsys 2010 for measurement of BNP and NT-proBNP[ J]. Clin Chim Acta,2006, 369( 1 ) :95-99.
  • 8Hogenhuis J, Voors A A, Jaarsma T, et al. Influence of age on natriuretic peptides in patients with chronic heart failure: a comparison between ANP/NT-ANP and BNP/NT-proBNP[J]. Eur J Heart Fail, 2005,7( 1 ) :81-86.
  • 9Peter J V, Hartley G G, Murakanli M M, et al. B-type natriuretic peptide (BNP) and N-terminal proBNP in obese patients without heart failure: Relationship to body mass index and gastric bypass surgery[J]. Clinical Chemistry, 2006,52(4) :680-685.

二级参考文献22

  • 1McCullough P A,Nowak R M,McCord J,et al.B-type natriuretic peptide and clinical judgement in emergency diagnosis of heart failure:analysis from Breathing Not Properly (BNP) Multinational study[J].Circulation,2002,106(4):419-422.
  • 2Tsutamoto T,Wada A,Meada K,et al.Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure-prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction[J].Circulation,1997.96(2):509-516.
  • 3Tsutamoto T,Wada A,Maeda K,et al.Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction-comparison with angiotensin Ⅱ and endothelin-1[J].Eur Heart J,1999,20(24):1799-1807.
  • 4Maeda K,Tsutamoto T,Wada A,et al.High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure[J].J Am Coll Cardiol,2000,36(5):1587-1593.
  • 5Harrison A,Morrison L K,Krishnaswamy P,et al.B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea[J].Ann Emerg Med,2002,39(2):131-138.
  • 6Maisel A S.Practical approaches to treating patients with acute decompensated heart failure[J].J Card Fail,2001,7(2 suppl 1):13-17.
  • 7Troughton R W,Frampton C M,Yandle T G,et al.Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations[J].Lancet,2000,355(9210):1126-1130.
  • 8Murdoch D R,McDonagh T A,Byrne J,et al.Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration:randomised comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy[J].Am Heart J,1999,138(6 PT 1):1126-1132.
  • 9Richards A M,Doughty R,Nicholls M G,et al.Neurohormonal prediction of benefit from carvedilol in ischemic left ventricular dysfunction.Australian New Zealand Heart Failure Group[J].Circulation,1999,99(6):786-792.
  • 10Waku S,Iida N,Ishihara T.Significance of brain natriuretic peptide measurement as a diagnostic indicator of cardiac function[J].Metholds Inf Med,2000,39(3):249-253.

共引文献45

同被引文献54

  • 1高海锋.肿瘤标记物CA125检测对肺癌的诊断价值[J].现代肿瘤医学,2008,16(11):1899-1900. 被引量:9
  • 2郭少磊,高美华,李武伦.CA125、CA72-4的检测在卵巢癌早期诊断中的临床价值[J].中国医疗前沿,2008,3(6):26-27. 被引量:7
  • 3杜巧茹,赵凯,刘志凡.甲亢患者心钠素水平观察[J].临床内科杂志,1994,11(2):32-33. 被引量:2
  • 4随华,刘纯.脑钠肽与内分泌疾病[J].国际内分泌代谢杂志,2006,26(3):181-183. 被引量:11
  • 5Maisel AS,Templin K,Love M,et al.Aprospective study of an algorithm using cardiac troponin I and myoglobin as adjuncts in the diagnosis of acute myocardial infarction and intermediate coronary syn dromes in a veteran's hospital[J].Clin Cardiol,2000,23(12):915-920.
  • 6Chocron S,Alwan W,Toubin G,et al.Effects of myocardial ischemia on the release of cardiac troponin I in isolated rat hearts[J].J Thoras Catdiovasc Surg,1996,112(2):508-513.
  • 7Jourdain P,Joudeau G,Funk F,et al.Plasma brain natriuretic pep-tide-guided therapy to improve outcome in heart failure:the STARS-BNP Multicenter Study[J].J Am Coll Cardiol,2007,49(16):1733-1739.
  • 8CLSI EP15-A2. User demonstration of performance for precision andaccuracy; Approved guideline-second Edition ( EP15-A2 ) [ S ]. Wayne : CLS1,2004.
  • 9CLSI EP17-A. Protocols for Determination of Limits of Detection and Limits of Quantitation ; Approved Guideline ( EP17-A ) [ S ]. Wayne : CLSI, 2004.
  • 10CLSI EP6-A. User demonstration of performance for precision and ac- curacy ; Approved Guideline (EP6-A) [ S ]. Wayne : CLS1,2004.

引证文献5

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部